Results 181 to 190 of about 718,683 (284)

PARP inhibitors synergize with abiraterone [PDF]

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

Targeting THOC2-Mediated mRNA Export Induces PARP Inhibitor Vulnerability in DNA Repair-Competent Hepatocellular Carcinoma. [PDF]

Int J Biol Sci
Li X, Yang S, Zhang M, Guo Z, Wang Y, Meng Y, Liu Y, Zhang H, Xu K, Zhang X, Zhai Y, Jin J, He F, Tian C, Sun A.   +14 more
europepmc   +1 more source

Decoding neuronal vulnerability: Multidimensional analysis of D1R‐ and D2R‐ medium‐sized spiny neurons in Huntington's disease

Brain Pathology, EarlyView.
D1R and D2R MSNs show distinct responses to Huntington's pathology. G&T‐sequencing of pre‐symptomatic MSNs reveals global LINE‐1 downregulation. While D1R‐MSNs display early transcriptomic changes (OXPHOS/translation upregulation) and reduced mutant huntingtin aggregation, D2R‐MSNs exhibit higher nuclear mHTT accumulation and greater CAG somatic ...
Guendalina Bergonzoni, Miguel Pellegrini, Aurora Savino, Martina Lazioli, Sarah Geurs, Lorenzo Graziani, Denise Ferrarini, Solaleh Khoramian Tusi, Esaria Oliver, Jarne Geurts, Sara Vinciguerra, Michele Tebaldi, Takshashila Tripathi, Isabella Pesce, Valeria Poli, Alessandro Romanel, Rosario Moratalla, Thierry Voet, Jasmin Morandell, Remo Sanges, Vanessa C. Wheeler, Erik Dassi, Marta Biagioli   +22 more
wiley   +1 more source

Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis. [PDF]

J Clin Med
Koksal B, Yildirim HC, Guven DC, Kose F, Koymen G, Ozdemir O, Ozberk U, Algin E, Guliyev M, Demirci NS, Alan O, Baklaci A, Demir B, Topkaya O, Uskent N, Yucel KB, Akdogan O, Koylu B, Selcukbiricik F, Bilgetekin I, Helvaci K, Unal A, Semiz HS, Sakalar T, Sever N, Cicek CM, Dogu GG, Biter S, Bayram E, Yildiz C, Demir H, Bayrakci I, Erdogan B, Kalender ME, Guzel HG, Ozturk B, Karabuga B, Ates O, Cetin EB, Sahbazlar M, Inal A, Sunar V, Basal FB, Asik E, Yildirim A, Oksuz NE, Urun Y, Nayir E, Turker S, On S, Aytac A, Menekse S, Temi YB, Uygun K, Sahin E, Keskinkilic M, Arik Z.   +56 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Expanding the horizons of PARP inhibitors [PDF]

Nature Reviews Cancer, 2010
openaire   +2 more sources

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Correction to 'USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance'. [PDF]

Nucleic Acids Res
europepmc   +1 more source

PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers. [PDF]

Int J Mol Sci
Dos Santos ES, Cicilini AL, Simões MFE, Baz M, Caputo SM, Rouleau E.   +5 more
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source